SCHIP compromise fails again

19 November 2007

A November 8 deadline to find a compromise in the long-standing efforts to renew and expand the States Children's Health Insurance Program (Marketletters passim) has passed without any resolution from the US House of Representatives. With President George W Bush having vowed to veto any move to raise the SCHIP entitlement threshold to 300% of the federal poverty line, as well as the proposal to fund the additional cost with a hike in tobacco taxes, the Democrat-controlled Congress has been attempting to secure enough support from the minority Republicans to get the two-thirds majority needed for a veto override.

One idea being touted would be to limit the expansion of the SCHIP's qualification threshold to 250% of the federal poverty line to states where the targeted number of households had been met for under 200% of poverty levels.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight